• About
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Partnerships
  • Products
    • Pipeline
    • Our Medicine
    • Tivozanib
    • Ficlatuzumab
    • AV-203
    • AV-380
    • AV-353
    • Expanded Access Policy
  • Publications & Presentations
  • Media
    • Press Releases
    • Media Toolkit
  • Investors
    • Overview
    • Corporate Governance
    • Stock Information
    • Research Coverage
    • Interactive Analyst Center
    • SEC Filings
    • Annual Reports
    • Press Releases
    • Scientific Publications & Presentations
    • Calendar of Events
    • FAQs
    • Information Request
  • Life at AVEO
    • Overview
    • Job Openings
  • Contact

Media

  • About
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Partnerships
  • Products
    • Pipeline
    • Our Medicine
    • Tivozanib
    • Ficlatuzumab
    • AV-203
    • AV-380
    • AV-353
    • Expanded Access Policy
  • Publications & Presentations
  • Media
    • Press Releases
    • Media Toolkit
  • Investors
    • Overview
    • Corporate Governance
    • Stock Information
    • Research Coverage
    • Interactive Analyst Center
    • SEC Filings
    • Annual Reports
    • Press Releases
    • Scientific Publications & Presentations
    • Calendar of Events
    • FAQs
    • Information Request
  • Life at AVEO
    • Overview
    • Job Openings
  • Contact

Click on the links below to download:

AVEO logo files (.zip 1.6MB)
Management photos (.zip 22.9MB)

Michael P. Bailey
President and CEO

For Media Inquiries, please contact:

John F. Kouten, CEO
JFK Communications, Inc.
jfkouten@jfkhealth.com
Direct: 609-241-7352

Tweets by AVEO

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)

###

© 2022 AVEO Pharmaceuticals, Inc. All rights reserved.
Terms of Use Privacy Policy
logo
  • About
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Partnerships
  • Products
    • Pipeline
    • Our Medicine
    • Tivozanib
    • Ficlatuzumab
    • AV-203
    • AV-380
    • AV-353
    • Expanded Access Policy
  • Publications & Presentations
  • Media
    • Press Releases
    • Media Toolkit
  • Investors
    • Overview
    • Corporate Governance
    • Stock Information
    • Research Coverage
    • Interactive Analyst Center
    • SEC Filings
    • Annual Reports
    • Press Releases
    • Scientific Publications & Presentations
    • Calendar of Events
    • FAQs
    • Information Request
  • Life at AVEO
    • Overview
    • Job Openings
  • Contact

This website may use certain types of cookies and other technologies to personalize content and to show more personalized ads. By clicking “Accept”, you understand that you are directing AVEO to disclose data that may be considered personal information to third parties for these purposes. For more details on what information we collect, why we collect it and to whom we disclose it, please visit our privacy policy.

aveo-oncology-logo
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

For more information about the data we collect please visit our Privacy Policy.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!